PHAXIAM Therapeutics S.A. (LON: 0QSS)
London
· Delayed Price · Currency is GBP · Price in EUR 1.820
+0.070 (4.00%)
Jan 21, 2025, 8:50 AM BST
PHAXIAM Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 2.14 | 1.33 | 6.65 | 4.18 | 3.72 | 5.28 | Upgrade
|
| Revenue | 2.14 | 1.33 | 6.65 | 4.18 | 3.72 | 5.28 | Upgrade
|
| Revenue Growth (YoY) | -64.15% | -80.05% | 59.02% | 12.43% | -29.62% | 18.80% | Upgrade
|
| Gross Profit | 2.14 | 1.33 | 6.65 | 4.18 | 3.72 | 5.28 | Upgrade
|
| Selling, General & Admin | 6.36 | 10.26 | 13.49 | 15.6 | 14.97 | 17.16 | Upgrade
|
| Research & Development | 13.89 | 10.91 | 18.61 | 45.1 | 57.58 | 52.19 | Upgrade
|
| Operating Expenses | 20.25 | 21.17 | 32.09 | 60.7 | 72.55 | 69.36 | Upgrade
|
| Operating Income | -18.11 | -19.85 | -25.45 | -56.52 | -68.83 | -64.07 | Upgrade
|
| Interest Expense | - | -0.2 | -0.32 | -2.14 | -2.16 | -0.49 | Upgrade
|
| Interest & Investment Income | 0.12 | 0.26 | 0.06 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.14 | -0.14 | 2.89 | 3.39 | -3.03 | 1.91 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | 0.04 | 0.07 | 1.45 | 0.71 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -18.09 | -19.88 | -22.74 | -53.8 | -73.3 | -62.66 | Upgrade
|
| Merger & Restructuring Charges | -3.81 | -3.81 | -1.7 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 24.35 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.39 | - | - | - | Upgrade
|
| Pretax Income | -21.9 | -23.7 | 0.29 | -53.8 | -73.3 | -62.66 | Upgrade
|
| Income Tax Expense | 0.02 | -0.21 | 0.52 | 0 | 0 | -0 | Upgrade
|
| Net Income | -21.92 | -23.49 | -0.23 | -53.8 | -73.3 | -62.66 | Upgrade
|
| Net Income to Common | -21.92 | -23.49 | -0.23 | -53.8 | -73.3 | -62.66 | Upgrade
|
| Shares Outstanding (Basic) | - | 5 | 3 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | - | 5 | 3 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | - | 51.38% | 30.91% | 28.86% | 2.50% | 0.00% | Upgrade
|
| EPS (Basic) | - | -5.00 | -0.07 | -22.71 | -39.87 | -34.93 | Upgrade
|
| EPS (Diluted) | - | -5.00 | -0.07 | -22.71 | -39.90 | -34.93 | Upgrade
|
| Free Cash Flow | - | -24.65 | -31.85 | -57.07 | -52.86 | -63.43 | Upgrade
|
| Free Cash Flow Per Share | - | -5.25 | -10.27 | -24.09 | -28.75 | -35.36 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -845.73% | -1496.76% | -382.83% | -1352.03% | -1851.32% | -1212.83% | Upgrade
|
| Profit Margin | -1023.91% | -1771.34% | -3.43% | -1287.01% | -1971.49% | -1186.05% | Upgrade
|
| Free Cash Flow Margin | - | -1858.60% | -479.13% | -1365.26% | -1421.71% | -1200.59% | Upgrade
|
| EBITDA | -18.9 | -19.65 | -23.27 | -52.49 | -65.36 | -62.28 | Upgrade
|
| D&A For EBITDA | -0.79 | 0.2 | 2.18 | 4.03 | 3.47 | 1.8 | Upgrade
|
| EBIT | -18.11 | -19.85 | -25.45 | -56.52 | -68.83 | -64.07 | Upgrade
|
| Effective Tax Rate | - | - | 177.82% | - | - | - | Upgrade
|
| Revenue as Reported | 2.14 | 1.33 | 31 | 4.18 | 3.72 | 5.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.